Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.62 |
| ▸ | ACHE | P22303 | 12/20 | 0.59 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | CA12 | O43570 | 2/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | CA2 | P00918 | 2/20 | 0.54 |
| ▸ | CA9 | Q16790 | 2/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28163838 | 0.98 | TDP1 (0.65) | TDP1MEN1KMT2AGAAACHE | |
| Ammonia Solution, Strong SCHEMBL4940325 | 0.98 | TDP1 (0.65) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL178408 | 0.94 | TDP1 (0.70) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL18875937 | 0.93 | MAOA (0.59) | TDP1MEN1KMT2AGAAACHE | |
| Acetic Acid Methyl Ester SCHEMBL7016956 | 0.93 | TDP1 (0.59) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL8270674 | 0.93 | MAOA (0.64) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL25319217 | 0.92 | TDP1 (0.73) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL7106115 | 0.92 | TDP1 (0.73) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL16436993 | 0.92 | TDP1 (0.73) | TDP1MEN1KMT2AGAAACHE | |
| SCHEMBL3365771 | 0.92 | TDP1 (0.73) | TDP1MEN1KMT2AGAAACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 418 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117510484-B | MIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-11-22 | — | — | CN | disclosed |
| EP-4423107-A1 | LIPID AMINES | ModernaTX, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-12029739-B2 | SHP2 inhibitor and use thereof | KANAPH THERAPEUTICS INC. (KR) | 2024-07-09 | — | — | US | disclosed |
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | MICROBIO (SHANGHAI) CO., LTD. (CN) | 2024-07-04 | — | — | US | disclosed |
| WO-2024123663-A1 | ANTIMICROBIAL COMPOUNDS | SRI INTERNATIONAL (US) | 2024-06-13 | — | — | WO | disclosed |
| WO-2024123914-A1 | PROCESS FOR MAKING ANTIBODY-DRUG CONJUGATES | MERCK SHARP & DOHME LLC (US) | 2024-06-13 | — | — | WO | disclosed |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | NEUROPN THERAPEUTICS (US) | 2024-06-04 | — | — | US | disclosed |
| CN-117510484-A | mIDH1/NAMPT double-target inhibitor and application thereof | 中国药科大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-25 | — | — | US | disclosed |
| WO-2024015412-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-01-18 | — | — | WO | disclosed |
| CN-1599738-A | Urea substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1599740-A | Amide substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | disclosed |
| CN-1599739-A | Sulfonamido substituted imidazopyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2005-03-23 | — | — | CN | disclosed |
| WO-2004094461-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2004-11-04 | — | — | WO | disclosed |
| WO-2004033427-A1 | 1,4-DISUBSTITUTED PIPERIDINE DERIVATIVES AND THEIR USE AS 11-BETAHSD1 INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-22 | — | — | WO | disclosed |
| WO-2004024060-A2 | METALLOPROTEINASE INHIBITORS AND INTERMEDIATES FOR PREPARATION THEREOF | ASTRAZENECA AB (SE) | 2004-03-25 | — | — | WO | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
| CN-1478090-A | Substituted imidazopyridines | 3M | 2004-02-25 | — | — | CN | disclosed |
| WO-2003033671-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MIMICS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-04-24 | — | — | WO | disclosed |
| WO-2001056358-A2 | ENHANCED PROPERTIED PESTICIDES | ROHM AND HAAS COMPANY (US) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025878-A1 | MDM2 DEGRADERS AND USES THEREOF | MDM2, TP53, MDM4 | TDP1 409/4885MEN1 2268/4885KMT2A 1193/4885 |
| US-20240218023-A1 | CYCLIC PEPTIDE-N-ACETYLGALACTOSAMINE (GALNAC) CONJUGATES FOR DRUG DELIVERY TO LIVER CELLS | GALNT1, CSGALNACT1, GALNT2 | TDP1 4042/4885MEN1 3147/4885KMT2A 3597/4885 |
| US-12029739-B2 | SHP2 inhibitor and use thereof | PTPN1, PTPN5, PTPN2 | TDP1 2327/4885MEN1 3025/4885KMT2A 1019/4885 |
| US-11998538-B2 | Piperidine urea derivatives as soluble epoxide hydrolase inhibitors | EPHX1, EPHX2, HPGDS | TDP1 2496/4885MEN1 4837/4885KMT2A 2930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.